




RealRate

PHARMACEUTICAL 2019

Histogen Inc.
Rank 161 of 371



RealRate

• Financial Strength Rankings using Artificial Intelligence • www.realrate.ai



RealRate

PHARMACEUTICAL 2019

Histogen Inc.
Rank 161 of 371



The relative strengths and weaknesses of Histogen Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Histogen Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 283% points. The greatest weakness of Histogen Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 202% points.

The company's Economic Capital Ratio, given in the ranking table, is -118%, being 213% points above the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	47,426
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	18,521
Liabilities, Non-Current	0
Other Assets	1,223
Other Compr. Net Income	60
Other Expenses	0
Other Liabilities	0
Other Net Income	267
Property and Equipment	154
Research and Development	41,368
Revenues	33,586
Selling, General and Administrative Expense	10,495

Output Variable	Value in 1000 USD
Assets	48,803
Liabilities	18,521
Expenses	51,863
Stockholders Equity	30,282
Net Income	-18,010
Comprehensive Net Income	-17,980
Economic Capital Ratio	-118%

